TGF-β1 protein expression in non-small cell lung cancers is correlated with prognosis

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 19, 2014, Pages 8143-8147

  Huang, Ai Li ^a   Liu, Shu Guang ^a   Qi, Wen Juan ^a   Zhao, Yun Fei ^a   Li, Yu Mei ^a   Lei, Bin ^a   Sheng, Wen Jie ^a   Shen, Hong ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

NSCLC; prognosis; quantitative analysis; transforming growth factor 1

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKER;

ADENOCARCINOMA; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; HUMAN; LARGE CELL CARCINOMA; LUNG; LUNG TUMOR; LYMPH NODE METASTASIS; MALE; METABOLISM; MIDDLE AGED; MORTALITY; NON SMALL CELL LUNG CANCER; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SECONDARY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

ADENOCARCINOMA; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKERS, BIOLOGICAL;

EID: 84908376980     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.19.8143     Document Type: Article

References (32)

1. Assoian RK, Komoriya A, Meyers CA, et al (1983). Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. J Biol Chem, 258, 7155-60.
2. Bai X, Shen H, Zhou C, et a1 (2009). Expression of thyroid transcription factor-l (TTF-1)in lung carcinomas and its correlations with apoptosis and angiogenesis. Clin Oncol Cancer Res, 6, 16-20.
3. Blobe GC, Schiemann WP, Lodish HF (2000). Role of transforming growth factor beta in human disease. N Engl J Med, 342, 1350-8.
4. Boyd FT, Massague J (1989). Transforming growth factor-beta inhibition of epithelial cell proliferation linked to the expression of a 53-kDa membrane receptor. J Biol Chem, 264, 2272-8.
5. Chen XF, Zhang HJ, Wang HB, et al (2012). Transforming growth factor-beta1 induces epithelial-to-mesenchymal transition in human lung cancer cells via PI3K/Akt and MEK/Erk1/2 signaling pathways. Mol Biol Rep, 39, 3549-56.
6. Derynck R, Akhurst RJ, Balmain A (2001). TGF-beta signaling in tumor suppression and cancer progression. Nat Genet, 29, 117-29.
7. Ellermeier J, Wei J, Duewell P, et al (2013). Therapeutic efficacy of bifunctional siRNA combining TGF-beta1 silencing with RIG-I activation in pancreatic cancer. Cancer Res, 73, 1709-20.
8. Furuta K, Misao S, Takahashi K, et al (1999). Gene mutation of transforming growth factor beta1 type II receptor in hepatocellular carcinoma. Int J Cancer, 81, 851-3.
9. Grady WM, Rajput A, Myeroff L, et al (1998). Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. Cancer Res, 58, 3101-4.
10. Tripsianis G, Papadopoulou E, Romanidis K, et al (2013). Overall survival and clinicopathological characteristics of patients with breast cancer in relation to the expression pattern of HER-2, IL-6, TNF-α and TGF-β1. Asian Pac J Cancer Prev, 14, 6813-20.
11. Janda E, Lehmann K, Killisch I, et al (2002). Ras and TGF cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J Cell Biol, 156, 299-313.
12. Jemal A, Siegel R, Ward E, et al (2007). Cancer statistics, 2007. CA Cancer J Clin, 57, 43-66.
13. Jennings MT, Pietenpol JA (1998). The role of transforming growth factor beta in glioma progression. J Neurooncol, 36, 123-40.
14. Kasai H, Allen JT, Mason RM, et al (2005). TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir Res, 6, 56.
15. Kim WS, Park C, Jung YS, et al (1999). Reduced transforming growth factor-beta type II receptor (TGF-beta RII) expression in adenocarcinoma of the lung. Anticancer Res, 19, 301-6.
16. Lei B, Liu S, Qi WJ, et al (2013). PBK/TOPK expression in non-small-cell lung cancer: its correlation and prognostic significance with Ki67 and p53 expression. Histopathology, 63, 696-703.
17. Luwor RB, Kaye, AH, Zhu HJ (2008). Transforming growth factor-beta (TGF-beta) and brain tumours. J Clin Neurosci, 15, 845-55.
18. Ma J, Gao H-M, Hua X, et al (2014). Role of TGF-β1 in human colorectal cancer and effects after cantharidinate intervention. Asian Pac J Cancer Prev, 15, 4045-8.
19. Markowitz S, Wang J, Myeroff L, et al (1995). Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science, 268, 1336-8.
20. Rich J, Borton A, Wang X (2001). Transforming growth factor-beta signaling in cancer. Microsc Res Tech, 52, 363-73.
21. Siegel PM, Massague J (2003). Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer, 3, 807-21.
22. Shen H, Lu Y (1993). Study on quantitative method of immunochemical staining. J Biomed Eng, 10, 281-4.
23. Shen H (1994). Study on quantitative method of intensity of immunohistochemical staining (II). J Cell Mol Immunol, 10, 33-5.
24. Shen H (1995). Study on quantitative method of immunochemical staining (III). Chin J Histochem Cytochem, 4, 89-92.
25. Takanami I, Imamura T, Hashizume T, et al (1994). Transforming growth factor beta 1 as a prognostic factor in pulmonary adenocarcinoma. J Clin Pathol, 47, 1098-100.
26. Takanami I, Tanaka F, Hashizume T, et al (1997). Roles of the transforming growth factor beta 1 and its type I and II receptors in the development of a pulmonary adenocarcinoma: results of an immunohistochemical study. J Surg Oncol, 64, 262-7.
27. Wan L, Li X, Shen H, et al (2013). Quantitative analysis of EZH2 expression and its correlations with lung cancer patients' clinical pathological characteristics. Clin Transl Oncol, 15, 132-8.
28. Wiedmann MW, Caca K (2005). Molecularly targeted therapy for gastrointestinal cancer. Curr Cancer Drug Targets, 5, 171-93.
29. Xu CC, Wu LM, Sun W, et al (2011). Effects of TGF-beta signaling blockade on human A549 lung adenocarcinoma cell lines. Mol Med Rep, 4, 1007-15.
30. Xu XY, Lin N, Li YM, et al (2013). Expression of HAb18G/ CD147 and its localization correlate with the progression and poor prognosis of non-small cell lung cancer. Pathol Res Pract, 209, 345-52.
31. Xue YJ, Lu Q, Sun ZX (2011). CD147 overexpression is a prognostic factor and a potential therapeutic target in bladder cancer. Med Oncol, 28, 1363-72.
32. Yanagisawa K, Uchida K, Nagatake M, et al (2000). Heterogeneities in the biological and biochemical functions of Smad2 and Smad4 mutants naturally occurring in human lung cancers. Oncogene, 19, 2305-11.